

# Programming assignment, R: Simulating Pathways, Mutual Exclusivity, et al. in Cancer Progression Models

Raquel Blanco Mart  nez-Illescas\*, Daniel Pe    as Utrilla\*, Henry Secaira Morocho\*

2021-01-20

## Contents

<b>1</b>	<b>Introduction</b>	<b>1</b>
1.1	Cancer Progression Models . . . . .	1
1.2	Evolutionary Models . . . . .	2
1.3	Order of effects . . . . .	2
1.4	Epistatic interactions . . . . .	2
1.4.1	Synththetic Viability . . . . .	2
1.4.2	Mutual exclusivity . . . . .	3
1.5	Frequency dependent fitness . . . . .	3
<b>2</b>	<b>pathTiMEx, a generative probabilistic graphical model of cancer progression</b>	<b>3</b>
2.1	Simplified cancer progression model . . . . .	6
2.2	Simulating data from a simplified model . . . . .	10
2.3	Order effects . . . . .	14
2.4	Epistasis to simulate order effects . . . . .	15
<b>3</b>	<b>Pathway Linear Progression Model: Raphael &amp; Vanding, 2015</b>	<b>18</b>
3.1	Simplified Model . . . . .	20
3.2	Simulating Data from Simplified Model . . . . .	23
3.3	Synthetic Lethality . . . . .	28
3.4	Synthetic Viability . . . . .	34
<b>4</b>	<b>A probabilistic model of mutually exclusive linearly ordered driver pathways</b>	<b>39</b>
4.1	Simplified cancer progression model . . . . .	43
4.2	Frequency-dependent fitness . . . . .	50

---

\*Universidad Aut    oma de Madrid, Bionformatics and Computational Biology Master

# 1 Introduction

## 1.1 Cancer Progression Models

Cancer is an heterogeneous disease caused by the continuous accumulation of different somatic mutations during lifetime of an individual (1). This somatic mutations include Single Nucleotide Variants (SNV), Copy Number Variations (CPV) or insertions and deletions (INDELS). However, not all mutations contribute to malignant initiation or cancer progression. Therefore, identifying mutation leading to cancer progression becomes key to understand cancer development and treatment (3). Somatic mutations that affect the cells are classified in two main groups: *passenger* mutations and *driver* mutations. Passenger mutations are silent mutations which doesn't lead to any pathogenic situation (these are the main alterations affecting cells). On the other hand, driver mutations are responsible for cancer onset. Those mutations provide the cells with morphological and metabolic alterations that ultimately lead to a selective growth advantage over wild type cells from which they derived (4).

Driver mutations can affect both oncogenes and tumor suppressor genes, but conversely. Oncogenes are altered proto-oncogenes leading to an uncontrolled growth rate, division and survival of cells. Thus, specific mutations promoting over-activation of these genes will yield to cancer onset. On the other hand, tumor suppressor genes prevent unrestrained cellular growth and promote DNA repair by protein recruitment. Furthermore, lower or abnormal expression of these genes threat DNA repair mechanisms and growth homeostasis (5).

Cancer progression is caused by the accumulation of various mutations not just simply one mutation as occurs in monogenic diseases. Moreover, not all possible mutations order seem to be equally responsible for cancer progression. Indeed, some mutations require some previous alteration to happen (dependencies between genes). Therefore, it is necessary to know which are the constraints and restrictions that lead to cancer development. Models explaining those dependencies are called **Cancer Progression Models (CPMs)** (6). CPMs are depicted as Directed Acyclic Graphs (DAG). In this graph, nodes represent genes and arrows dependencies between them. The path refers to the order of mutations to cancer progression (7).

Although cancer progression is a dynamic process, tumor data is usually obtained as **cross-sectional** samples. It is a combination of snapshots taken from different tumor progression at different stages (2). Assuming that these observations reflect the same stochastic process, they can be used to infer restrictions between tumor events. This order of effects can be report as a direct graph. Knowing this constraints between genes, it allows to define a therapeutic target to avoid cancer progression (7). However, temporal progression of any cancer is difficult to infer by cross-sectional data. The utopian dataset to infer cancer progression is a *longitudinal dataset* consisting of same individual tumor samples from different time points during cancer development. Nevertheless, it is almost impossible without damaging individuals (1).

## 1.2 Evolutionary Models

Previous studies have inferred the alterations (passenger and driver genes) and the order in which they occur during cancer progression using generative probabilistic models (8). Those methods use Oncogenic Trees (OT) and Conjunctive Bayesian Networks (CBN) to impose restrictions in the occurrence of mutations. As discussed in (6), in such methods a mutation in a driver gene can occur only if the preceding parent mutations have occurred, this is known as **monotonicity**. Nevertheless, it is not realistic to have a single set of restrictions for all genotypes, since genotypes can follow different paths during disease progression (6). Thus, OTs and CBNs cannot be used to address deviations from monotonicity (6). However, Evolutionary tumor progression models can incorporate the order restrictions from OTs and CBNs and allow us to analyze the consequences of deviations from monotonicity and the genetic context in which a mutation appears (6). Moreover, fitness landscapes can be used to understands the consequences of different evolutionary scenarios

in CPMs, such as the possible paths of tumor progression and identification of genes that can block those paths (7).

### 1.3 Order of effects

The order in which somatic mutations are acquired influence clonal evolution, since mutations may behave as driver or passenger depending on the genetic context (6). Three mechanisms may contribute to the influence of order of effects (10). First, the initial mutation can alter the cellular environment of a neoplastic clone. Then, as a consequence, the second mutation will arise in a cellular environment determined by the first mutation (10). Second, the initial mutation can alter cellular pathways as targets for subsequent mutations (10). Third, the initial mutation can modify the epigenetic program of cells and thus alter the consequences of the second mutation (10). Therefore, the fitness of a mutation depends in which mutations were acquired previously. It is important to mention that order of effects from the restrictions imposed in a DAG, since in restrictions the fitness of a double mutant does not depend on which mutation was acquired first (11).

### 1.4 Epistatic interactions

Epistasis is defined as a deviation from the expected phenotype when combining two alleles (12). Cancer progression is driven by the accumulation of somatic mutations that interact epistatically, that is their effect is non-additive to the tumor fitness as a phenotype (12). For example, combinations of mutations that show positive epistasis result in a stronger fitness increase (stronger than the additive effects of individual mutations) (13). On the other hand, mutations that show negative epistasis result in fitness decrease (less than expected from their additive effects) (13). Therefore, mutations that show positive fitness are more likely to co-occur, whereas mutations that show negative fitness are rarely observed together resulting in mutual exclusivity (13). Moreover, reciprocal sign epistasis (see below) affect the ruggedness and lead to multiple peaks (a signature of epistasis) in the fitness landscape (7).

#### 1.4.1 Synthetic Viability

Synthetic viability is the combination of two mutations that rescue the lethal effects of each single mutation (15). The idea of synthetic viability has been recently applied to identify genomic markers for drug resistance prediction and drug-combination for anti-cancer therapy (15).

#### 1.4.2 Mutual exclusivity

Mutual exclusivity is a common phenomenon in cancer progression (13) and occurs by synthetic lethality (described below) and null effect. This phenomenon is common in cancer signaling pathways (13). Synthetic lethality (or reciprocal sign epistasis) occurs when combination of two mutations is detrimental for the viability of the cell, whereas each individual mutation is not (7). On the other hand, the null effect states that a mutation that occurs first involves most of the selective advantage and thus decrease the selective pressure for others mutations to arise (13).

### 1.5 Frequency dependent fitness

(Just an idea) Describe frequency dependent fitness

In this work, we mapped DAGs inferred from three different generative probabilistic models to actual tumor evolutionary models by allowing deviations from monotonicity using functions of the **OncoSimulR** package. Moreover, we simulated other relevant scenarios for cancer progression, such as order of effects, epistatic interactions (synthetic lethality, synthetic viability), and frequency-dependent fitness. In addition,

we mapped the genotypes of our evolutionary models to fitness landscape in order to gain a better knowledge of mutational paths during tumor progression. Similarly, we did simulations of tumor progression to understand the effect of fitness associated to each genotype.

## 2 pathTiMEx, a generative probabilistic graphical model of cancer progression

In (8), the authors introduce a generative probabilistic graphical model of cancer progression called *path-TiMEx*. It is both, a waiting time model for independent mutually exclusive pathways, and a waiting time model for cancer progression among single genes.

This generative model allows to generate a cancer progression model including mutual exclusivity between groups and progression among pathways. In this approach, authors think in both, genes and modules effects (set of genes).

The colorectal cancer model depicted in Figure 3.A (8) is used as an example of model to map. The colorectal cancer dataset used to built that model is obtained from (16). The poset restrictions proposed can be coded using the **OncoSimulR** package (11), concretely, the **allFitnessEffects** function. It creates mutations effects given specification of restrictions, epistasis or order effects. In this case, restrictions are used to construct the graph.

Some parameters are mandatory when **allFitnessEffects** function is used. It is the case of the *restriction table*. It specifies the dependencies between genes or modules (genes/modules parents and genes/module children). Parameter **s** and **sh** refers to a numeric vector with the fitness effect that applies if the relationship is or is not satisfied, respectively. Authors don't specify its value since they are not interested in fitness. To justify the values given, we will use the waiting time rate parameter  $\lambda$  defined in the model. Early events in cancer progression will have greater  $\lambda$  values while late events will have a lower one (values for all genes or modules are showed in Table 1). Thus, genes/modules with higher  $\lambda$  will receive a higher fitness value (**s**). On the other hand, **sh** is given a constant value for all possible situations.

Table 1: Waiting time rate parameter ( $\lambda$ ) for each gene/module

Gene/module	Waiting time rate parameter ( $\lambda$ )
APC	9.5
KRAS	2.89
TP53, EVC2	1.92
PIK3CA, EPHA3	0.17
FBXW7, TCF7L2	0.08

Although authors don't specify the sort of dependency, in this poset, a semimonotonic dependency is defined between modules B and C with E (**SM**), while a monotonic dependency is defined for the others (**MN**). Model will be represented as an **Diacyclic Direct Graph (DAG)** where arrows connecting genes or modules indicate direct dependencies or constraints between them (7).

```
## First, it is necessary to load OncoSimulR and igraph package
library(OncoSimulR)
```

```

## Restriction table (extended version of the poset)
colcancer <- data.frame(
  parent = c(rep("Root",3), "A", "B", "C"), # Parent nodes
  child = c("A", "B", "D", "C", "E", "E"), ## Child nodes
  s = c(rep(0.5, 3), rep(0.05, 3)),

  sh = -0.5,

  typeDep = c(rep("MN", 4), rep("SM", 2)) ## Type of dependency
)

## Fitness specification of the poset
colcancer_efec <- allFitnessEffects(
  colcancer, # Poset

  geneToModule = c( ## Specification of the modules
    "Root" = "Root",
    "A" = "APC",
    "B" = "TP53, EVC2",
    "C" = "KRAS",
    "D" = "PI3KCA, EPHA",
    "E" = "FBXW7, TCF7L2"),

  drvNames = c( ## Specification of drivers
    "APC", "TP53", "EVC2", "KRAS",
    "PI3KCA", "EPHA", "FBXW7", "TCF7L2")
)

## DAG representation
plot(colcancer_efec, expandModules = TRUE, autofit = TRUE, lwdf = 2)

```

Model proposed by (8) indicates that, from a wild type genotype (depicted as “Root” in Figure 1) it is possible to follow three different paths. The wild type genotype can suffer a mutation in the APC gene or in the TP53, EVC2 or PI3KCA, EPHA modules. These mutations occur independently, without the need for previous mutations to occur.

In the case of the PI3KCA, EPHA module, it is not essential for other mutated genes or modules to appear. On the other hand, the mutation in the APC gene is necessary for a mutation to occur in the KRAS gene. The APC gene is the parent node of the KRAS gene (**monotonicity dependency**). Also, the KRAS gene would be necessary for the mutation to appear in the FBXW7, TCF7L2 module. However, the relationship of the KRAS gene to the FBXW7, TCF7L2 module has been defined as a **semitonicity dependency**. This implies that there is no need for a mutation in the TP53, EVC2 module in order for it to mutate. Similarly, a mutation in the TP53, EVC2 module would be sufficient for a mutation in the FBXW7, TCF7L2 module to occur (this semitonicity dependency is depicted in blue color in Figure 1).

In a DAG, only the genotypes that fulfill the restrictions defined by the arrows connecting the genes/modules can exist. Moreover, restrictions set in DAG do not contain any information about fitness of each individual genotypes, it is just a pathway to follow to cancer progression. On the other hand, fitness landscapes (or genotype-fitness maps) show the fitness associated to each genotype allowing to know the impact of a specific mutation. Furthermore, the restrictions reflected in the DAG just show sign epistasis between genes/modules. Epistasis is an effect where the phenotypic consequences of a certain mutation depend on the genetic background in which it takes place.




Figure 1: DAG from colorecta cancer

A specific type of epistasis is called *sign epistasis* and it refers to the case where a mutation yields to a increase (beneficial) or decrease (deleterious) of the fitness depending on the genotypic background of the cell. It has a different sign depending on the other genes mutated in the clone cell. Although this kind of epistasis can be depicted using a DAG, it can not show reciprocal sign epistasis, a specific situation where two individual mutations increase the fitness, although combine reduce it (synthetic lethality).

Hence, to visualize the relationships between genotypes and effects in fitness, the fitness landscape using the restrictions specified in Figure 1 is generated. For that aim, the `evalAllGenotypes` function is used. It returns a table with all the genotypes from the fitnessEffects description indicated as well as the genotype associated to it. The table obtained can be used as an object to plot a fitness landscape of the Figure 1.

```
colcancer_efec_FL <- evalAllGenotypes(colcancer_efec, max = 110000)
## Output is not shown due to size of the table.

## Plot of fitness landscape
plotFitnessLandscape(colcancer_efec_FL)
```




Figure 2: Fitness landscape from colorectal cancer

Fitness landscape obtained is displayed in Figure 2. It shows a quite busy fitness landscape due to the huge amount of possible genotypes combinations, each one with a different fitness value. However, it reflects genotype acquisition in terms of survival and adaptation for the cell, allowing to set what is the fitness associated to a clone that gets a certain mutations or a certain number of them.

## 2.1 Simplified cancer progression model

In order to properly visualize a fitness landscape, a simplified version of the model coded in [section 2](#) is constructed. This model doesn't use modules, just individual genes. This approach will lead to clear fitness landscape and to properly identify processes that may occur.

Authors (8) claim that there is a phenomena of mutual exclusivity between certain genes of specific pathways. Mutual exclusivity means that the presence of one gene in a specific pathway will be enough to fitness contribution, since mutation in the other genes of the same pathway are negative selected and therefore, the presence of the other gene in the same module can be discarded, since they will not mutate.

Therefore, the same model as in the previous case will be coded, but without specifying modules. Each module will be consider as an specific gene.

```
## Fitness specification of the simplified poset  
Scolcancer <- allFitnessEffects(colcancer)
```

```
plot(Scolcancer)
```




Figure 3: DAG from a simplified model of colorecta cancer

```
## Obtain all genotypes from the fitnessEffect  
(Scolcancer_ge <- evalAllGenotypes(Scolcancer))
```

```
##           Genotype  Fitness
```



```

## 1          A 1.500000
## 2          B 1.500000
## 3          C 0.500000
## 4          D 1.500000
## 5          E 0.500000
## 6      A, B 2.250000
## 7      A, C 1.575000
## 8      A, D 2.250000
## 9      A, E 0.750000
## 10     B, C 0.750000
## 11     B, D 2.250000
## 12     B, E 1.575000
## 13     C, D 0.750000
## 14     C, E 0.525000
## 15     D, E 0.750000
## 16  A, B, C 2.362500
## 17  A, B, D 3.375000
## 18  A, B, E 2.362500
## 19  A, C, D 2.362500
## 20  A, C, E 1.653750
## 21  A, D, E 1.125000
## 22  B, C, D 1.125000
## 23  B, C, E 0.787500
## 24  B, D, E 2.362500
## 25  C, D, E 0.787500
## 26  A, B, C, D 3.543750
## 27  A, B, C, E 2.480625
## 28  A, B, D, E 3.543750
## 29  A, C, D, E 2.480625
## 30  B, C, D, E 1.181250
## 31 A, B, C, D, E 3.720938

```

```


## Plot the fitness landscape.
plotFitnessLandscape(Scolcancer_ge,
                     use_ggrepel = TRUE)

```

DAG graph and fitness landscape of this simplified model is depicted in [Figure 3](#) and [Figure 4](#), respectively. DAG showed in [Figure 3](#) is the same as the DAG depicted in [Figure 1](#) but without expanding modules. In this case, there is not an improvement in legibility or clarity. However, if we compare the fitness landscape obtained with the simplification (see [Figure 4](#)) with the previous fitness landscape (see [Figure 2](#)), there are a clear difference in clarity. In this new fitness landscape is possible to visualize the fitness given to each genotype and therefore, give an evolutionary sight to the model.

## 2.2 Simulating data from a simplified model

Restrictions set in DAG were used as a guide line to built the fitness landscape (see [Figure 4](#)). This fitness landscape shows each possible genotype as well as its fitness. This landscape can be used to simulate fitness evolution in cancer progression. `OncoSimulIndiv` function is used to simulate colorectal tumor progression. This function simulates a single evolutionary path. It is necessary to include the poset with the order restrictions defined for the simplified model (see [subsection 2.1](#)). McFarland model (continuous-time, logistic-like, and death rate depends on population size) is used for simulation of cancer progression, since it leads to a better performance ([6](#)). Initial population size is set at 400. Only one mutation rate is used:  $1e-4$ . Final



time is set to 220 to visualize clones' evolution. Furthermore, keepPhylog parameter is set true to plot the parent-child relationships occurring in the simulation as well as its frequency (plotClonePhylog function).

```
set.seed(257) ## Fix the seed for reproducibility

Simul <- oncoSimulIndiv(Scolcancer, ## A fitnessEffects object
  model = "McFL", ## Model used
  mu = 1e-4, ## Mutation rate
  sampleEvery = 0.02, ## How often the whole population is sampled
  keepEvery = 1,
  initSize = 400, ## Initial population size
  finalTime = 220,
  keepPhylog = TRUE, ## Allow to see parent-child relationships
  onlyCancer = FALSE
)

## Plot of simulation
plot(Simul, ## OncoSimulIndiv model
  show = "genotypes",
  type = "stacked"
)
```




Figure 5: Simulation of cancer progression using the fitness landscape of the simplified model (stacked plot)

```
## Plot of simulation
plot(Simul, ## OncoSimulIndv model
     show = "genotypes",
     type = "line"
)
```




Figure 6: Simulation of cancer progression using the fitness landscape of the simplified model (line plot)

```
## Parent-child relationship derived from simulation
plotClonePhylog(Simul,
                 N = 0, ## Specify clones that exist
                 keepEvents = TRUE ## Arrows showing how many times each clones appeared
)
```

A stacked and line plot of the simulation is depicted in [Figure 5](#) and [Figure 6](#), respectively. Both plots show the genotype acquisition by time and the number of clones carrying that genotype in the cell culture. Different cell population converge in different time moments, each carrying a different genotype and therefore, a different fitness.

In [Figure 5](#) wild type genotype (“WT”) progressively disappears while clones carrying a mutation in gene “A” arrive to culture. However, they are substituted by a new clone that also carries a mutation in “B”. Then, this clone suffers different mutations resulting in the coexistence of different genotypes in the cell culture, each one with a different fitness. Finally, genotype carrying all genotypes is stabilized in the culture. As it




Figure 7: Parent-child relationship derived from simulation

fitness is the greatest among all the fitness of all genotypes. It is obvious that it is more selective favored and it will overcome the concurrence with the other genotypes.

On the other hand, [Figure 6](#) shows the same information but it is possible to observe all genotypes generated in the simulation, even those that survive for little time. In addition to the genotypes seen in [Figure 5](#), some other genotypes appear in the cell culture, but due to selective pressure, they are not able to survive.

Hence, genotypes observed in the simulation not only follow the restrictions set in DAG of [section 2](#). It is just a generative model where dependencies between genes are defined, but they may not occur in real life in that order. Moreover, this model is constructed using cross-sectional data, tumor snapshots in a specific time of cancer progression, it is not a temporal dataset from the onset to the end of the cancer progression.

[Figure 7](#) shows the genotype evolution in the simulation. Arrows' width represent frequency of clone creation. Widther arrows indicate a higher frequency of change from the parent genotype to the child genotype.

## 2.3 Order effects

To explore order effects in cancer progression, a simple model derived from the restriction model inferred by (8) is created.

This simplified model just contains 3 genes: APC, TP53 and KRAS, genes considered as **superdrivers** (17), meaning that are the main responsible for cancer progression since they provide a higher fitness gain than the other genes in the model. This conclusion is obtained from its article where they used the same colorectal cancer dataset as (8). Thus, it can be extrapolated to our case.

The relationships between those genes was previously depicted in [section 2](#). In this case, we will set APC as the parent of KRAS. Both, APC and TP53 have as parent Root. Based on the waiting time rate parameter  $\lambda$ , the fitness values of each possible order is given (see [Table 1](#)).

$\lambda$  is higher for APC, which means that it seems to appear before in the cancer progression.  $\lambda$  for KRAS is the lower between the three, meaning that it mutates the last. TP53 mutation occurs between APC and KRAS. Order effects are defined following this criteria: clones suffering mutations in the previous order are favored with a higher fitness. Other possible paths of cancer progression are slightly less naturally selected (assumption based on (8)). Order effect is visualize using `evalAllGenotypes` function.

```
cc <- data.frame(parent = c(rep("Root", 2), "A"),
  child = c("A", "C", "B"),
  typeDep = "MN")

cc_order <- allFitnessEffects(
  orderEffects = c("A > B > C" = 0.5, "B > A > C" = 0.2,
    "B > C > A" = 0.1,
    "B > C" = 0.2,
    "C > B" = 0.1,
    "B > A" = 0.1,
    "A > B" = 0.3),

  geneToModule =
    c("A" = "APC",
      "B" = "KRAS",
      "C" = "TP53") )

(cc_order_genotype <- evalAllGenotypes(cc_order, order = TRUE))
```

```
##          Genotype Fitness
## 1          APC      1.000
```

```
## 2          KRAS  1.000
## 3          TP53  1.000
## 4      APC > KRAS  1.300
## 5      APC > TP53  1.000
## 6      KRAS > APC  1.100
## 7      KRAS > TP53  1.200
## 8      TP53 > APC  1.000
## 9      TP53 > KRAS  1.100
## 10 APC > KRAS > TP53  2.340
## 11 APC > TP53 > KRAS  1.430
## 12 KRAS > APC > TP53  1.584
## 13 KRAS > TP53 > APC  1.452
## 14 TP53 > APC > KRAS  1.430
## 15 TP53 > KRAS > APC  1.210
```

We obtain a table with the different possible genotypes as well as the order of appearance. However, this approach doesn't allow to generate neither a DAG neither a fitness landscape. Thus, is not possible to visualize the evolution of the genotypes with time.

```
#DAG
plot(cc_order)
```

```
## Error in `*tmp*`[[i]]: subíndice fuera de los límites
```

```
# Fitness landscape
plotFitnessLandscape(cc_order_genos)
```

```
## Error in to_Fitness_Matrix(x, max_num_genotypes = max_num_genotypes): We cannot deal with order effects
```

Assuming a model where there is not an order effect, a mutation in gene “B” followed by a mutation in gene “A” will reach the same fitness as if the mutation in gene “A” occurs first. However, in the model just generated, the order of the mutation impacts the final fitness reached by the tumoral clone. Since, the previous alteration of some genes before can lead to an evolutionary advantage.

In a non order effect model, the final fitness value is the same for all the clones, while this is unlikely to happen in real life. Clones carrying a certain mutation from the beginning would survive easily than those reaching the same genotype in a different order.

This is one limitation of `OncoSimulR` package, it doesn't allow to visualize those scenarios (yet).

## 2.4 Epistasis to simulate order effects

Epistasis assume that there is a dependence between genotypes. The effect of a mutation depends on the genetic background in which it happens (18). Now, we will cope with dependencies between genes using epistasis.

For that, we will use the same model described in subsection 2.3. As explained before, it is supposed to be a certain cancer progression restriction and therefore, the fitness values given to each different genotype is based in that criteria.

```

## Fitness object defined using epistasis
cc_epi <- allFitnessEffects(epistasis =
  c("A: -B: -C" = 0.4,
    "-A: B: -C" = -0.4,
    "-A: -B: C" = 0.3,
    "A: B: -C" = 0.8,
    "A : B: C" = 1.4,
    "-A: B: C" = 0.1,
    "A : -B: C" = 0.5
  ),
  geneToModule =
  c("A" = "APC",
    "B" = "KRAS",
    "C" = "TP53")
)

## DAG (epistasis)
plot(cc_epi, expandModules = TRUE, autofit = TRUE)

```




Figure 8: DAG showing epistasis between genes

```

## Genotypes derived from fitness defined with epistasia relationships
(cc_epi_geno <- evalAllGenotypes(cc_epi ))

```

```

##          Genotype Fitness

```



```
## 1          APC      1.4
## 2          KRAS     0.6
## 3          TP53     1.3
## 4      APC, KRAS    1.8
## 5      APC, TP53    1.5
## 6      KRAS, TP53   1.1
## 7 APC, KRAS, TP53  2.4
```

```
## Fitness landscape from this relationships
plotFitnessLandscape(cc_epi_genos, use_ggrepel = TRUE)
```




Figure 9: Fitness landscape of model defined by epistasis

Using this approach, it is possible to visualize the DAG (see Figure 8). In this case, there are discontinuous yellow lines connecting each gene. These lines indicate a dependence between them. Fitness landscape is also plotted (see Figure 9).

With this model, we promote the clones of tumoral cells beginning with a first mutation in APC. Conversely, other clones not starting with that mutation (KRAS or TP53) have a lower fitness value. On the other hand, all genotypes end with the same fitness, but it is selective favored clones following the order defined in subsection 2.3. Hence, epistasis cannot be used to define order effects, but it can be used as a temporal solution.

### 3 Pathway Linear Progression Model: Raphael & Vanding, 2015

The Pathway Linear Progression Model (PLPM) described in (1) introduces the idea that driver mutations target pathways. This is an important concept since different individuals have driver mutations in different genes that affect the same pathway (1). Therefore, the order in which mutations arise are better described at the pathway level instead of a gene level (1).

Here, we mapped the progression model from colorectal cancer data inferred by (1) (originally described in (16)) into an evolutionary model, allowing deviations from the restriction imposed in the DAG. For this, we used a vector **s** to indicate the fitness effects when the restrictions are satisfied and a vector **sh** for deviations.

In (1), the authors analyzed eight genes: APC, EPHA3, EVC2, FBXW7, KRAS, PIK3CA, TCF7L2, and TP53. In this model, APC mutations is an early event, followed by mutations in TP53 and PIK3CA (mutually exclusive). KRAS mutations appear after TP53/PIK3CA mutations.

We used the `allFitnessEffects` function to define the nodes and their relationships. Moreover, we used modules to represent mutually exclusive genes that affect the same pathway. Assigned fitness effects (**s**) values were higher for earlier mutations and lower for late mutation, since an earlier mutation is more prevalent in the clonal population than a later mutation, as explained in (19). A single negative value was set for deviations from restrictions (**sh**) and a monotonic relationship (MN) was used for relationships between nodes of the DAG since nodes have only one parent.

Figure 10 shows the DAG inferred by (1) mapped to an evolutionary model that allows deviation from restrictions. Note that genes within a module are mutually exclusive and the restrictions goes top-down (i.e. from the root to the later mutation).

```
## Define poset restrictions, mapping of genes to modules, and driver genes
CRC_W <- allFitnessEffects(data.frame(parent = c("Root", "A", "B", "C"),
                                       child = c("A", "B", "C", "D"),
                                       s = c(0.6, 0.4, 0.1, 0.05),
                                       sh = -0.5,
                                       typeDep = "MN"),
                           geneToModule = c("Root" = "Root",
                                             "A" = "APC, EPHA3, TCF7L2",
                                             "B" = "EVC2, PIK3CA, TP53",
                                             "C" = "KRAS",
                                             "D" = "FBXW7"),
                           drvNames = c("APC", "EPHA3", "TCF7L2", "EVC2", "PIK3CA",
                                          "TP53", "KRAS", "FBXW7"))

# DAG representation
plot(CRC_W, expandModules = TRUE, autofit = TRUE, lwdf = 2)
```

The function `evalAllGenotypes` was used to map genotypes to fitness values. Figure 11 shows the fitness landscape inferred from the DAG of Figure 10. As mentioned before, this fitness landscape with eight genes is difficult to visualize. Nevertheless, we can give a general description of the topology of the landscape. Note that there are multiple peaks and valleys, suggesting a high degree of ruggedness. Moreover, note that KRAS constitutes a local minima. This results confirms the order of restrictions imposed by the DAG. It is important to mention that some genotypes in the local maxima are composed of genes that belong to the same module. Such genes participate in the same pathway and are mutually exclusive. Nevertheless, modules does not allow to capture this idea. A combinations of order of restrictions (XOR relationships) and epistatic interactions are able to better simulate mutual exclusivity (see below).

```
## Map genotypes to fitness
CRC_F <- evalAllGenotypes(CRC_W, order = FALSE, addwt = TRUE)
```




Figure 10: DAG from colorectal cancer dataset

```
## Plot of fitness landscape
```

```
plot(CRC_F)
```




Figure 11: Fitness landscape inferred from colorectal cancer DAG

### 3.1 Simplified Model

Given that our initial DAG contains eight genes, then number of possible genotypes is  $2^8 = 256$  which makes difficult to visualize the fitness landscape. For this, reason a smaller number of genes will be used to build a slightly different DAG to model other interesting scenarios (see Figure 12). The idea is to represent mutual exclusivity with a XOR relationship (red edges). Also, note that the fitness value for mutual exclusive genes (APC and TP53) is almost the same.

```
## Simplified model
## Define poset restrictions, mapping of genes to modules, and driver genes
CRC_W2 <- allFitnessEffects(data.frame(parent = c(rep("Root", 2), "A", "B", "C"),
  child = c("A", "B", rep("C", 2), "D"),
  s = c(0.2, 0.1, rep(0.05, 2), 0.01),
  sh = -0.5,
  typeDep = c(rep("XMPN", 4), "MN")),
  geneToModule = c("Root" = "Root",
    "A" = "APC",
```

```

        "B" = "TP53",
        "C" = "KRAS",
        "D" = "FBXW7"),
    drvNames = c("APC", "TP53", "KRAS", "FBXW7"))

# DAG representation
plot(CRC_W2, expandModules = TRUE, autofit = TRUE, lwdf = 2)

```




Figure 12: Simplified model from colorectal cancer DAG

Since only four genes are used in the DAG, then the possible number of genotypes is  $2^4 = 16$ , which are easier to interpret in a fitness landscape (see Figure 13). Now, the genotypes with the highest fitness are the ones that fulfill the order of restrictions imposed by the DAG (e.g. APC, FBXW7, KRAS - APC, FBXW7, KRAS, TP53). On the other hand, genotypes that deviates from the imposed restrictions have the lowest fitness (e.g. KRAS - FBXW7 - APC, KRAS, TP53). However, specifying mutual exclusivity with XOR relationships cannot capture null effect or synthetic lethality between APC and TP53. Also, if an AND relationship is defined from the Root to APC and TP53, then there is no change in fitness values.

```

## Simplified Model
## Map genotypes to fitness
(CRC_F2 <- evalAllGenotypes(CRC_W2, order = FALSE, addwt = TRUE))

```

```

##          Genotype Fitness
## 1          WT 1.00000

```

```

## 2          APC 1.20000
## 3          FBXW7 0.50000
## 4          KRAS 0.50000
## 5          TP53 1.10000
## 6          APC, FBXW7 0.60000
## 7          APC, KRAS 1.26000
## 8          APC, TP53 1.32000
## 9          FBXW7, KRAS 0.50500
## 10         FBXW7, TP53 0.55000
## 11         KRAS, TP53 1.15500
## 12         APC, FBXW7, KRAS 1.27260
## 13         APC, FBXW7, TP53 0.66000
## 14         APC, KRAS, TP53 0.66000
## 15         FBXW7, KRAS, TP53 1.16655
## 16 APC, FBXW7, KRAS, TP53 0.66660

```

```
## Plot of fitness landscap
```

```
plot(CRC_F2, use_ggrepel = TRUE)
```




Figure 13: Fitness landscape from simplified model

## 3.2 Simulating Data from Simplified Model

Fitness effects and restrictions defined in the DAG from Figure 12 from previous section was used to simulate clonal evolution. The same parameters from subsection 2.2, except `initSize` and `finalTime`, were set in the `OncoSimulIndiv` function. Figure 14 shows the genotypes during that arises during clonal evolution. The genotype APC, TP53 fixates quickly in the clonal population. This result supports the fitness value for APC, FBXW7, KRAS depicted in Figure 13, since that genotype is one of the local maxima. A more detailed order of genotype appearances and extinctions is shown in Figure 15. Note that not all the 16 genotypes appear in the simulation because the best fitted genotype fixates rapidly in the population, leading to the extinction of some genotypes, whereas other cannot even appear. When simulation were executed with `onlyCancer = TRUE`, cancer is never reached, although the fixated genotype is the global maxima of the fitness landscape (see Figure 16 and Figure 17).

```
## Fix the seed for reproducibility
set.seed(87)

CRC_W2_S <- oncoSimulIndiv(CRC_W2, ## A fitnessEffects object
  model = "McFL", ## Model used
  mu = 1e-4, ## Mutation rate
  sampleEvery = 0.02, ## How often the whole population is sampled
  keepEvery = 1,
  initSize = 2000, ## Initial population size
  finalTime = 2000,
  keepPhylog = TRUE, ## Allow to see parent-child relationships
  onlyCancer = FALSE)

## Plot of simulation for genotypes
plot(CRC_W2_S,
  show = "genotypes",
  type = "stacked")
```

```
## Plot of simulation for genotypes
plot(CRC_W2_S,
  show = "genotypes",
  legend.ncols = 2,
  xlim = c(0, 1500),
  type = "line")
```

```
## Fix the seed for reproducibility
set.seed(52)

CRC_W2_S1 <- oncoSimulIndiv(CRC_W2, ## A fitnessEffects object
  model = "McFL", ## Model used
  mu = 1e-4, ## Mutation rate
  sampleEvery = 0.02, ## How often the whole population is sampled
  keepEvery = 1,
  initSize = 2000, ## Initial population size
  finalTime = 800,
  keepPhylog = TRUE, ## Allow to see parent-child relationships
  onlyCancer = TRUE,
```




Figure 14: Simulation of cancer progression for the simplified model. Genotypes are shown stacked






Figure 15: Simulation of cancer progression for the simplified model. Genotypes are shown as lines.

```
errorHitWallTime = FALSE, ## See results even if stopping conditions are not met
errorHitMaxTries = FALSE)
```

```
##
## Hitted maxtries. Exiting.
```

```
## Time to reach cancer
(CRC_W2_S1$FinalTime)
```

```
## [1] 800
```

```
## Plot of simulation for genotypes
plot(CRC_W2_S1,
show = "genotypes",
legend.ncols = 2,
xlim = c(0, 500),
type = "stacked")
```




Figure 16: Simulation of cancer progression for the simplified model when onlyCancer = TRUE. Genotypes are shown stacked.

```
## Plot of simulation for genotypes
```

```
plot(CRC_W2_S1,  
show = "genotypes",  
legend.ncols = 1,  
xlim = c(0, 300),  
type = "line")
```




Figure 17: Simulation of cancer progression for the simplified model when onlyCancer = TRUE. Genotypes are shown as lines.

Figure 18 and Figure 19 shows the genealogical relationships of clones that appeared during the simulations. The number of the arrows represent the times that each clone appeared. When simulation are set to reach cancer the clones that have a genotype belonging to the two local optima appear (Figure 19). Whereas if simulation are executed without the cancer parameter, the most represented clone is the one that has the best fitted genotype (see Figure 18).

```
## Plot of genealogical relationships
```

```
plotClonePhylog(CRC_W2_S, N = 0, keepEvents = TRUE)
```

```
## Plot of genealogical relationships
```

```
plotClonePhylog(CRC_W2_S1, N = 0, keepEvents = TRUE)
```




Figure 18: Genealogical relationships of clones.



### 3.3 Synthetic Lethality

Synthetic lethality is a special type of epistasis. Therefore, we used the epistasis module inside `allFitnessEffects` to define an epistatic interaction between TP53 and AP (see Figure 20) and restriction imposed by the DAG (i.e. XOR relationships). The fitness values were assigned such that an scenario where synthetic lethality via pairwise interaction occurs.

The fitness landscape shows that the genotype for which the synthetic lethality was specified has a lower fitness value as expected, although it is not a local minima. Similarly to fitness landscape in Figure 13, the local maxima is composed by the genotypes that satisfy both epistatic interactions and restrictions imposed. Whereas, local minima is composed by genotypes that contain genes with synthetic lethality and other genes that have top-down dependencies (see Figure 21).

```
## Simplified model
## Define poset restrictions, mapping of genes to modules, and driver genes
CRC_W3 <- allFitnessEffects(data.frame(parent = c(rep("Root", 2), "A", "B", "C"),
  child = c("A", "B", rep("C", 2), "D"),
  s = c(0.2, 0.1, rep(0.05, 2), 0.01),
  sh = -0.5,
  typeDep = c(rep("XMPN", 4), "MN")),
  epistasis = c("-A : B" = 0.1,
    "-B : A" = 0.2,
    "A:B" = -0.5),
  geneToModule = c("Root" = "Root",
    "A" = "APC",
    "B" = "TP53",
    "C" = "KRAS",
    "D" = "FBXW7"),
  drvNames = c("APC", "TP53", "KRAS", "FBXW7"))

# DAG representation
plot(CRC_W3, expandModules = TRUE, autofit = TRUE, lwdf = 2)
```

```
## Map genotypes to fitness
CRC_F1 <- evalAllGenotypes(CRC_W3, order = FALSE, addwt = TRUE)

(CRC_F1)
```

##	Genotype	Fitness
## 1	WT	1.000000
## 2	APC	1.440000
## 3	FBXW7	0.500000
## 4	KRAS	0.500000
## 5	TP53	1.210000
## 6	APC, FBXW7	0.720000
## 7	APC, KRAS	1.512000
## 8	APC, TP53	0.660000
## 9	FBXW7, KRAS	0.505000
## 10	FBXW7, TP53	0.605000
## 11	KRAS, TP53	1.270500
## 12	APC, FBXW7, KRAS	1.527120
## 13	APC, FBXW7, TP53	0.330000
## 14	APC, KRAS, TP53	0.330000




Figure 20: DAG with synthetic lethality.

```
## 15      FBXW7, KRAS, TP53 1.283205
## 16 APC, FBXW7, KRAS, TP53 0.333300
```

```
## Plot of fitness landscape
```

```
plot(CRC_F1, use_ggrepel = TRUE)
```




Figure 21: Fitness landscape inferred from simplified DAG with synthetic lethality.

In order to simulate synthetic lethality via three-way interaction, we set fitness values that reflect slightly deleterious effect (if two genes appear) or a highly deleterious effect (if three genes appear). Figure 22 shows the DAG derived for the three-way interaction between APC, TP53, and KRAS. The inferred fitness landscape shows that the global minima is composed by the genotype that carries the synthetic lethality. Whereas, local maxima is composed by genotypes that follow the restrictions imposed in the DAG. Also, note that the global maxima is APC. This is not surprising given that APC is an earlier mutation and has the highest fitness values compared to other genes/genotypes (see Figure 23).

```
## Simplified model
```

```
## Define poset restrictions, mapping of genes to modules, and driver genes
```

```
CRC_W4 <- allFitnessEffects(data.frame(parent = c(rep("Root", 2), "A", "B", "C"),
  child = c("A", "B", rep("C", 2), "D"),
  s = c(0.2, 0.1, rep(0.05, 2), 0.01),
  sh = -0.5,
  typeDep = c(rep("XMPN", 4), "MN")),
  epistasis = c("A : -B : -C" = 0.2,
```



```

        "-A : B : -C" = 0.1,
        "-A : -B : C" = 0.05,
        "A : B : -C" = 0.01,
        "-A : B : C" = 0.02,
        "-B : A : C" = 0.02,
        "A : B : C" = -0.5),
geneToModule = c("Root" = "Root",
                  "A" = "APC",
                  "B" = "TP53",
                  "C" = "KRAS",
                  "D" = "FBXW7"),
drvNames = c("APC", "TP53", "KRAS", "FBXW7"))

# DAG representation
plot(CRC_W4, expandModules = TRUE, autofit = TRUE, lwdf = 2)

```




Figure 22: DAG with synthetic lethality (three-way interaction).

```

## Map genotypes to fitness
CRC_F2 <- evalAllGenotypes(CRC_W4, order = FALSE, addwt = TRUE)

(CRC_F2)

```

```

##          Genotype  Fitness

```

```

## 1          WT 1.000000
## 2          APC 1.440000
## 3          FBXW7 0.500000
## 4          KRAS 0.525000
## 5          TP53 1.210000
## 6          APC, FBXW7 0.720000
## 7          APC, KRAS 1.285200
## 8          APC, TP53 1.333200
## 9          FBXW7, KRAS 0.530250
## 10         FBXW7, TP53 0.605000
## 11         KRAS, TP53 1.178100
## 12         APC, FBXW7, KRAS 1.298052
## 13         APC, FBXW7, TP53 0.666600
## 14         APC, KRAS, TP53 0.330000
## 15         FBXW7, KRAS, TP53 1.189881
## 16        APC, FBXW7, KRAS, TP53 0.333300

```

```

## Plot of fitness landscape
plot(CRC_F2, use_ggrepel = TRUE)

```




Figure 23: Fitness landscape inferred from simplified DAG with synthetic lethality (three-way interaction).

### 3.4 Synthetic Viability

Synthetic viability is specified for genotype APC, TP53 (see Figure 24). Here the genotypes composed only by APC or TP53 are deleterious. Figure 25 shows the fitness landscape for synthetic viability via pairwise interaction. Note that the global maxima is composed by the genotype that contains all genes. On the other hand, local minima is composed by genotypes that contains one gene that has a deleterious effect. Note that despite the lower fitness value of genotype FBXW7, KRAS, it conforms a local maxima, although the restrictions imposed in the DAG are not completely satisfied. Moreover, in this fitness landscape, the global maxima may not be reached because the mutational paths required lead to a region composed of multiple valleys. It is important to mention that order of effects could provide a more realistic fitness landscape. For example, a possible path that leads to the global maxima requires a mutation in KRAS before a mutation in FBXW7.

```
## Simplified model
## SM because synthetic viability requires both parent nodes.
## Define poset restrictions, mapping of genes to modules, and driver genes
CRC_W5 <- allFitnessEffects(data.frame(parent = c(rep("Root", 2), "A", "B", "C"),
                                         child = c("A", "B", rep("C", 2), "D"),
                                         s = c(0.2, 0.1, rep(0.05, 2), 0.01),
                                         sh = -0.5,
                                         typeDep = c(rep("MN", 5))),
                             epistasis = c("-A : B" = -0.2,
                                           "-B : A" = -0.3,
                                           "A:B" = 0.5),
                             geneToModule = c("Root" = "Root",
                                                "A" = "APC",
                                                "B" = "TP53",
                                                "C" = "KRAS",
                                                "D" = "FBXW7"),
                             drvNames = c("APC", "TP53", "KRAS", "FBXW7"))

# DAG representation
plot(CRC_W5, expandModules = TRUE, autofit = TRUE, lwdf = 2)
```

```
## Map genotypes to fitness
CRC_F3 <- evalAllGenotypes(CRC_W5, order = FALSE, addwt = TRUE)
(CRC_F3)
```

##	Genotype	Fitness
## 1	WT	1.00000
## 2	APC	0.84000
## 3	FBXW7	0.50000
## 4	KRAS	0.50000
## 5	TP53	0.88000
## 6	APC, FBXW7	0.42000
## 7	APC, KRAS	0.42000
## 8	APC, TP53	1.98000
## 9	FBXW7, KRAS	0.50500
## 10	FBXW7, TP53	0.44000
## 11	KRAS, TP53	0.44000
## 12	APC, FBXW7, KRAS	0.42420
## 13	APC, FBXW7, TP53	0.99000
## 14	APC, KRAS, TP53	2.07900




Figure 24: DAG with synthetic viability (pairwise interaction).

```
## 15      FBXW7, KRAS, TP53 0.44440
## 16 APC, FBXW7, KRAS, TP53 2.09979
```

```
## Plot of fitness landscape
```

```
plot(CRC_F3, use_ggrepel = TRUE)
```




Figure 25: Fitness landscape inferred from simplified DAG with synthetic viability.

Figure 26 shows synthetic viability with a three-way interaction between APC, TP53, and KRAS. For this, we specified highly deleterious effects if APC, TP53, or KRAS appear independently. Whereas, slightly deleterious effects were set if two of those genes appear in a genotype. The fitness landscape for this scenario (see Figure 27) shows the order of restrictions and epistatic interactions set lead to the global maxima composed by the genotype APC, TP53, KRAS, FBXW7. This result support the idea that DAGs are better suited to represent sign epistasis (7). Nevertheless, as mentioned above, including order of effects can give a more realistic fitness values associated to genotypes.

In this work, we have represented synthetic lethality via pairwise and three-way interactions. However, this can be achieved if the DAG is composed by individual genes instead of modules because modules does not allow to define epistatic relationships between genes of the same module. This is important because genes of the same module can participate in the same pathway, as discussed in (2).

```
## Simplified model
```

```
## SM because synthetic viability requires both parent nodes.
```

```
## Define poset restrictions, mapping of genes to modules, and driver genes
```

```

CRC_W6 <- allFitnessEffects(data.frame(parent = c(rep("Root", 2), "A", "B", "C"),
  child = c("A", "B", rep("C", 2), "D"),
  s = c(0.2, 0.1, rep(0.05, 2), 0.01),
  sh = -0.5,
  typeDep = c(rep("MN", 5))),
  epistasis = c("A : -B : -C" = -0.2,
    "-A : B : -C" = -0.2,
    "-A : -B : C" = -0.3,
    "A : B : -C" = -0.05,
    "-A : B : C" = -0.01,
    "A : -B : C" = -0.01,
    "A : B : C" = 0.5),
  geneToModule = c("Root" = "Root",
    "A" = "APC",
    "B" = "TP53",
    "C" = "KRAS",
    "D" = "FBXW7"),
  drvNames = c("APC", "TP53", "KRAS", "FBXW7"))

# DAG representation
plot(CRC_W6, expandModules = TRUE, autofit = TRUE, lwdf = 2)

```




Figure 26: DAG with synthetic viability (three-way interaction).

```
## Map genotypes to fitness
CRC_F4 <- evalAllGenotypes(CRC_W6, order = FALSE, addwt = TRUE)
(CRC_F4)
```

```
##          Genotype  Fitness
## 1          WT 1.000000
## 2          APC 0.960000
## 3        FBXW7 0.500000
## 4          KRAS 0.350000
## 5          TP53 0.880000
## 6    APC, FBXW7 0.480000
## 7    APC, KRAS 0.594000
## 8    APC, TP53 1.254000
## 9    FBXW7, KRAS 0.353500
## 10   FBXW7, TP53 0.440000
## 11   KRAS, TP53 0.544500
## 12   APC, FBXW7, KRAS 0.599940
## 13   APC, FBXW7, TP53 0.627000
## 14   APC, KRAS, TP53 2.079000
## 15   FBXW7, KRAS, TP53 0.549945
## 16   APC, FBXW7, KRAS, TP53 2.099790
```

```
## Plot of fitness landscape
plot(CRC_F4, use_ggrepel = TRUE)
```

## 4 A probabilistic model of mutually exclusive linearly ordered driver pathways

Mohaghegh Neyshabouri et al. (9) propose a probabilistic model of mutually exclusive linearly ordered driver pathways and analyze one large dataset of colorectal adenocarcinoma (COADREAD) from IntOGen-mutations database. Their model assumes driver genes are over-represented among those mutated across a large tumor collection and, thus, they can be identified in terms of frequency. Also, those participating of the same pathway are mutated in a mutually exclusive manner because more than one mutation in a pathway does not give any selective advantage to the clone.

Like with previous generative models, we map the COADREAD generative model to an actual evolutionary model using different **OncoSimulR** functionalities. This time, we extent what authors model using the frequency-dependent fitness specification, to illustrate how differently fitness landscapes evolve even though they are built from exact CPMs when we consider this additional evolutionary event

Figure 7.C from (9) shows the CPM inferred from the COADREAD dataset, consisting of seven modules with between 1 to 4 genes each. The model clearly reconstructs the well-known initiator events in colorectal cancer, including mutations in *APC*, *TP53* and *KRAS* (17). Using the DAG of restrictions as starting point<sup>1</sup>, the evolutionary model is created specifying same genotype fitness for all modules as authors do not state any differences in fitness for when the restrictions in the DAG are satisfied (s). However, based on the confidence parameter used by the authors to assess the reliability of modeled restrictions, different fitness are set when the DAG of restrictions is not satisfied (sh) (Table 2). Since this method reconstructs linear models (*i.e.* oncogenic trees), there is no need to specify any particular type of dependency between modules

<sup>1</sup>Several genes were removed from the original set in order to get a clear fitness landscape




Figure 27: Fitness landscape inferred from simplified DAG with synthetic viability (three-way interaction).



(typeDep), so we set it to monotonic (MN) as it is a mandatory argument for `allFitnessEffects` function. Figure 28 shows the DAG of restrictions created with `allFitnessEffects`, recapitulating the poset inferred in (9).

Table 2: confidence parameter for each module transition

Module	Confidence parameter (%)
APC	100
TP53	100
KRAS	100
PIK3CA, NRAS, LRP1B	100
FBXW7, TCF7L2, FAT4, ARID1A	87.7
ATM, SMAD2, ERBB3, MTOR, CTNNB1	86.9
SOX9, SMAD4	66.7

```
## Restriction table, including DAG of restrictions specifications and associated fitness
COADREAD_rT <- data.frame(parent = c("Root", "A", "B", "C", "D", "E", "F"), # Parent nodes
  child = c("A", "B", "C", "D", "E", "F", "G"), # Child nodes
  s = 0.5,
  sh = c(rep(-1, 4), rep(-.5, 2), -.2),
  typeDep = "MN")

## Create fitness specifications from DAG of restrictions considering modules
COADREAD_fitness <- allFitnessEffects(COADREAD_rT,
  geneToModule = c( "Root" = "Root",
    "A" = "APC",
    "B" = "TP53",
    "C" = "KRAS",
    "D" = "PIK3CA, NRAS",
    "E" = "FBXW7, ARID1A",
    "F" = "ATM, SMAD2",
    "G" = "SOX9, SMAD4")) # Modules

## DAG of restrictions representation
plot(COADREAD_fitness, expandModules = TRUE, autofit = TRUE)

# Evaluation of all possible genotypes fitness under the previous fitness specifications
COADREAD_FL <- evalAllGenotypes(COADREAD_fitness, max = 131072)

# Fitness landscape representation
plotFitnessLandscape(COADREAD_FL)
```

Figure 29 plots all possible genotypes in a very busy fitness landscape. Although it is not possible to visualize genotypes clearly, we can see an exponential trend towards local maxima, corresponding to the




Figure 28: DAG of restrictions for the COADREAD dataset




Figure 29: Fitness landscape corresponding with the DAG of restrictions for the COADREAD dataset

clones carrying seven driver-genes genotypes. Stands out how very different genotypes behave the same due to the mutual exclusivity effect, which is probably simplifying much more complex interactions among genes, specially the effect in fitness different genes from the same module could have if we didn't account for the mutual exclusivity phenomenon. In next section we discuss genotypes distribution with a simplified model.

## 4.1 Simplified cancer progression model

As we did with previous models, for illustrating purposes we designed a simplified version of the CPM by (9) to assess its reliability when considering other evolutionary scenarios. This time, we take the first four modules of the complete DAG (maintaining same fitness parameters), being the fourth the only one carrying two genes and, thus, affected by mutual exclusivity circumstance (Figure 30).

The fitness landscape shown in ?? includes some of the possible genotypes. Clearer than in Figure 29, we see fitness increases exponentially following the restrictions established in the DAG. Local minima (red squares) correspond to genotypes violating these constraints, and gain changes (green lines) are consistent with satisfied restrictions. However, one of the local maxima genotypes (green squares) corresponds to a genotype violating mutual exclusivity (PIK3CA and NRAS appear together). This is explained because the Modules functionality in OncoSimulR sets fitness to zero when genes from the same module mutate at a time as there is a null effect because both genes participate from the same pathway. Because there is not a decrease in the fitness of the genotype (*iei* no deleterious effect), it can still be a local maxima. Yet, it is unlikely a genotype needed of an extra mutation to compete with the other maximum-fitness genotypes will survive long during cancer progression to fixate. DE TODAS FORMAS, AQUÃ IRÃ A LO QUE SEA QUE NOS DIGA RAMÃ N.

```
## Restriction table, including five-modules DAG of restrictions specifications and associated fitness
COADREAD_rT_5d <- data.frame(parent = c("Root", "A", "B", "C"), # Parent nodes
                             child = c("A", "B", "C", "D"), # Child nodes
                             s = 0.5,
                             sh = c(rep(-1, 4)),
                             typeDep = "MN")

## Create fitness specifications from simplified DAG of restrictions
COADREAD_fitness_5d <- allFitnessEffects(COADREAD_rT_5d,
                                         geneToModule = c( "Root" = "Root",
                                                            "A" = "APC",
                                                            "B" = "TP53",
                                                            "C" = "KRAS",
                                                            "D" = "PIK3CA, NRAS"),
                                         drvNames = c("APC", "TP53", "KRAS",
                                                       "PIK3CA", "NRAS"))

## Simplified DAG of restrictions representation
plot(COADREAD_fitness_5d, expandModules = TRUE, autofit = TRUE)

# Evaluation of all possible genotypes fitness under the previous fitness specifications
COADREAD_FL_5d <- evalAllGenotypes(COADREAD_fitness_5d)

# Fitness landscape representation
plotFitnessLandscape(COADREAD_FL_5d, use_ggrepel = TRUE)

## Warning: ggrepel: 22 unlabeled data points (too many overlaps). Consider
## increasing max.overlaps
```




Figure 30: Simplified DAG of restrictions for the COADREAD dataset




Figure 31: Fitness landscape corresponding with the simplified DAG of restrictions for the COADREAD dataset

```
plotFitnessLandscape(COADREAD_FL_5d)
```




Figure 32: Fitness landscape corresponding with the simplified DAG of restrictions for the COADREAD dataset

The previous assumption can be better addressed simulating tumor progression under the proposed evolutionary model. Accordingly, we would expect clones to evolve following the optimal pathway of the fitness landscape, that is satisfying the DAG of restrictions. We use `oncoSimulPop` function to simulate tumor progression in ten different individuals and test whether the genotype APC, TP53, KRAS, PIK3CA, NRAS would ever fixate even at a very small frequency. Parameters are adjusted appropriately so that simulation stops when APC, TP53, KRAS, PIK3CA, NRAS genotype is reached at a frequency of 0.1 at least (`onlyCancer = TRUE`, `fixation = c(c("_", APC, TP53, KRAS, PIK3CA, NRAS"), fixation_tolerance = 0.9)`).

Figure 33 shows a representative stacked plot of the genotype abundance over time. Surprisingly, APC, TP53, KRAS, PIK3CA, NRAS genotype appeared in the ten simulations significantly (Data not shown), able to coexist with clones of the same fitness. Often, it arises from APC, TP53, KRAS, PIK3CA or APC, TP53, KRAS, NRAS clones, which appear together even less frequently, probably because both descend from the same ancestor and have much higher fitness, leading to its extinction once one of the two emerges. Figure 34 supports this idea as it clearly plots the behavior of each clone separately, displaying abrupt extinctions the moment the following clone with higher fitness appears. Retrieving the phylogeny of the clones (representative graph of one simulation in Figure 35), we confirm there is a tendency of the clones to mutate until the complete genotype APC, TP53, KRAS, PIK3CA, NRAS, either following the linear mutual exclusivity path or from a more diverse landscape.

```

set.seed(125)

# Simulate cancer progression in 10 individuals until APC, TP53, KRAS, PIK3CA, NRAS genotype fixates
COADREAD_Simul_5d <- oncoSimulPop(10, COADREAD_fitness_5d,
  model = "McFL", ## Model used
  mu = 1e-4, ## Mutation rate
  sampleEvery = 0.02, ## How often the whole population is sampled
  keepEvery = 1,
  initSize = 200, ## Initial population size
  finalTime = 2000,
  keepPhylog = TRUE, ## Allow to see parent-child relationships
  onlyCancer = TRUE,
  detectionSize = NA,
  fixation = c(c("_", APC, TP53, KRAS, PIK3CA, NRAS"),
    fixation_tolerance = 0.7),
  detectionDrivers = NA,
  detectionProb = NA,
  max.num.tries = 500,
  max.wall.time = 20,
  errorHitMaxTries = TRUE)

## You are running Windows. Setting mc.cores = 1

```

```

## Plot of simulation for genotypes
plot(COADREAD_Simul_5d[[3]],
  show = "genotypes",
  type = "stacked",
  ylim = c(0, 35000))

```

```

plot(COADREAD_Simul_5d[[5]],
  show = "genotypes",
  type = "line",
  ylim = c(1, 100000000))

```

```

## Parent-child relationship derived from simulation
plotClonePhylog(COADREAD_Simul_5d[[3]],
  N = 0, ## Specify clones that exist
  keepEvents = TRUE ## Arrows showing how many times each clones appeared
)

```

## 4.2 Frequency-dependent fitness

As previously introduced, clones that coexist in a tumor can influence the fitness of each other in a frequency-dependent manner when a mutation produces a phenotype able to modulate the tumor microenvironment. OncoSimulR incorporates the `frequencyDependentFitness` specification to allow modelling interactions among clones during tumor progression. In the simulations ran with the simplified model, we significantly observed APC, TP53, KRAS, PIK3CA, NRAS genotype in the final stage of the simulation, an unexpected event considering PIK3CA and NRAS are mutually exclusive. This might denote there is an additional evolutionary event directing the very infrequent coexistence of these two genes in tumor samples ((9)). Here, we






Figure 33: One of the 10 simulations of cancer progression using the four-modules fitness landscape until APC, TP53, KRAS, PIK3CA, NRAS genotype arises (stacked plot)




Figure 34: One of the 10 simulations of cancer progression using the four-modules fitness landscape until APC, TP53, KRAS, PIK3CA, NRAS genotype arises (line plot)




Figure 35: Parent-child relationship derived from one of the 10 simulations

propose APC, TP53, KRAS, PIK3CA, NRAS genotype fitness could depend on the frequency of APC, TP53, KRAS, PIK3CA and APC, TP53, KRAS, NRAS genotypes in the context of a competitive relationship among clones for niche nutrients. APC, TP53, KRAS, PIK3CA, NRAS clones would be more energetically demanding and thus, coexistence with other clones would be detrimental (considering the three clones have same fitness).

To use the `frequencyDependentFitness` functionality, it is necessary to set to `TRUE` the `frequencyDependentFitness` parameter in the `allFitnessEffects` function, as well as providing a “mapping of genotypes to fitness” data frame. Fitness values are taken from the fitness specifications previously used (??). To evaluate genotypes with the `evalAllGenotypes` function is mandatory the parameter `spPopSizes` to build a fitness landscape in accordance with the size of the different clones. Here, we define a scenario in which all the clones except for the four-genes and five-genes clones are almost extinct. In this context, we already see in the fitness landscape (Figure 36) an expected fitness decreased in APC, TP53, KRAS, PIK3CA, NRAS genotype, which is not a local maxima anymore.

```
## Mapping of genotypes to frequency-dependent fitness
# Not explicitly mapped genotypes are assigned a fitness of zero
COADREAD_gen_freqdep <- data.frame(Genotype = c("WT", "APC", "APC, TP53",
                                                "APC, TP53, KRAS",
                                                "APC, TP53, KRAS, PIK3CA",
                                                "APC, TP53, KRAS, NRAS",
                                                "APC, TP53, KRAS, PIK3CA, NRAS"),
                                   Fitness = c("1", "1.5", "2.25", "3.375", "5.0625", "5.0625",
                                                "5.0625 - ((f_APC_TP53_KRAS_PIK3CA + f_APC_TP53_KRAS_NRAS))/2"),
                                   stringsAsFactors = FALSE)

## Fitness specifications

COADREAD_fitness_freqdep <- allFitnessEffects(genotFitness = COADREAD_gen_freqdep,
                                              frequencyDependentFitness = TRUE,
                                              frequencyType = "rel")

## Evaluate all genotypes considering population sizes of the clones
COADREAD_FL_freqdep <- evalAllGenotypes(COADREAD_fitness_freqdep,
                                       spPopSizes = c("WT" = 5, "APC" = 5, "APC, TP53" = 5,
                                                       "APC, TP53, KRAS" = 10,
                                                       "APC, TP53, KRAS, PIK3CA" = 50,
                                                       "APC, TP53, KRAS, NRAS" = 50,
                                                       "APC, TP53, KRAS, PIK3CA, NRAS" = 50))

# Fitness landscape representation
plotFitnessLandscape(COADREAD_FL_freqdep)
```

Next, we try to run the same simulation we did before with these new fitness specifications. After modifying the `fixation_tolerance` parameter so that we could detect the APC, TP53, KRAS, PIK3CA, NRAS genotype rapidly, it never arises. This can be explained by its slightly lower fitness compare to its ancestors, which by the moment PIK3CA or NRAS mutate to generate the fivefold-mutated genotype have a very high frequency, slowing down APC, TP53, KRAS, PIK3CA, NRAS clone growth up to extinction. Running an additional short simulation, in which we just set `onlyCancer` as `FALSE` (so as for the simulation to run until `finalTime`), in Figure 37 we don't see the presence of the fivefold-mutated clone, yet Figure 38 shows an oscillating pattern of growth for this clone. Also, the phylogeny recorded for each simulation shows the appearance of APC, TP53, KRAS, PIK3CA, NRAS genotype (Figure 39). Either way, its frequency is so low that it cannot trigger the `onlyCancer` condition to end the first simulation. Although we cannot assure whether the phenomenon



of frequency-dependent fitness could be influencing on the lack of coexistence of PIK3CA and NRAS in real colorectal cancer samples ((9)), these findings support there are probably additional evolutionary events leading genotype frequency apart from mutual exclusivity.

```
# Simulate cancer progression in 10 individuals until APC, TP53, KRAS, PIK3CA, NRAS genotype fixates
```

```
set.seed(125)
COADREAD_Simul_freqdep <- oncoSimulIndiv(COADREAD_fitness_freqdep,
  model = "McFL", ## Model used
  mu = 1e-4, ## Mutation rate
  sampleEvery = 0.02, ## How often the whole population is sampled
  keepEvery = 1,
  initSize = 200, ## Initial population size
  finalTime = 2000,
  keepPhylog = TRUE, ## Allow to see parent-child relationships
  onlyCancer = TRUE,
  detectionSize = NA,
  fixation = c(c("_", APC, TP53, KRAS, PIK3CA, NRAS"),
    fixation_tolerance = 0.99),
  detectionDrivers = NA,
  detectionProb = NA)
```

```
##
## Hitted wall time. Exiting.
## Hitting wall time is regarded as an error.
```

```
# Simulate cancer progression in 10 individuals for a final time of 300 time units
```

```
set.seed(125)
COADREAD_Simul_freqdep <- oncoSimulPop(10, COADREAD_fitness_freqdep,
  model = "McFL", ## Model used
  mu = 1e-4, ## Mutation rate
  sampleEvery = 0.02, ## How often the whole population is sampled
  keepEvery = 1,
  initSize = 200, ## Initial population size
  finalTime = 300,
  keepPhylog = TRUE, ## Allow to see parent-child relationships
  onlyCancer = FALSE,
  detectionSize = NA,
  fixation = NA,
  detectionDrivers = NA,
  detectionProb = NA)
```

```
## You are running Windows. Setting mc.cores = 1
```

```
## Plot of simulation for genotypes
plot(COADREAD_Simul_freqdep[[9]],
  show = "genotypes",
  type = "stacked",
  ylim = c(0, 35000))
```




Figure 37: One of the 10 simulations of cancer progression using the frequency-dependent fitness model for the COADREAD dataset (stacked plot)

```
plot(COADREAD_Simul_freqdep[[9]],
     show = "genotypes",
     type = "line",
     ylim = c(1, 100000000))
```




Figure 38: One of the 10 simulations of cancer progression using the frequency-dependent fitness model for the COADREAD dataset (line plot)

```
## Parent-child relationship derived from simulation
plotClonePhylog(COADREAD_Simul_freqdep[[9]],
                 N = 0, ## Specify clones that exist
                 keepEvents = TRUE ## Arrows showing how many times each clones appeared
)
```

## 5 References

1. Raphael BJ, Vandin F. Simultaneous Inference of Cancer Pathways and Tumor Progression from Cross-Sectional Mutation Data. *Journal of Computational Biology*. 2015;22(6):510–27. doi: [10.1089/cmb.2014.0161](https://doi.org/10.1089/cmb.2014.0161)
2. Schill R, Solbrig S, Wettig T, Spang R. Modelling cancer progression using Mutual Hazard Networks. *Bioinformatics*. 2020;36(1):241–9. doi: [10.1093/bioinformatics/btz513](https://doi.org/10.1093/bioinformatics/btz513)






Figure 39: Parent-child relationship derived from one of the 10 simulations

3. Pon JR, Marra MA. Driver and passenger mutations in cancer. *Annual Review of Pathology: Mechanisms of Disease*. 2015; doi: [10.1146/annurev-pathol-012414-040312](https://doi.org/10.1146/annurev-pathol-012414-040312)
4. Nowell PC. The clonal evolution of tumor cell populations. *Science*. 1976; doi: [10.1126/science.959840](https://doi.org/10.1126/science.959840)
5. Lee EYHP, Muller WJ. Oncogenes and tumor suppressor genes. 2010. doi: [10.1101/cshperspect.a003236](https://doi.org/10.1101/cshperspect.a003236)
6. Diaz-Uriarte R. Identifying restrictions in the order of accumulation of mutations during tumor progression: Effects of passengers, evolutionary models, and sampling. *BMC Bioinformatics*. 2015;16(1):1–26. doi: [10.1186/s12859-015-0466-7](https://doi.org/10.1186/s12859-015-0466-7)
7. Diaz-Uriarte R. Cancer progression models and fitness landscapes: A many-to-many relationship. *Bioinformatics*. 2018;34(5):836–44. doi: [10.1093/bioinformatics/btx663](https://doi.org/10.1093/bioinformatics/btx663)
8. Cristea S, Kuipers J, Beerenwinkel N. PathTiMEX: Joint Inference of Mutually Exclusive Cancer Pathways and Their Progression Dynamics. *Journal of Computational Biology*. 2017;24(6):603–15. doi: [10.1089/cmb.2016.0171](https://doi.org/10.1089/cmb.2016.0171)
9. Neyshabouri MM, Jun SH, Lagergren J. Inferring tumor progression in large datasets. *PLoS Computational Biology*. 2020;16(10):1–16. Available from: <http://dx.doi.org/10.1371/journal.pcbi.1008183>
10. Ortmann CA, Kent DG, Nangalia J, Silber Y, Wedge DC, Grinfeld J, et al. Effect of Mutation Order on Myeloproliferative Neoplasms. *New England Journal of Medicine*. 2015 Feb;372(7):601–12. [accessed 20 Jan 2021] Available from: <https://doi.org/10.1056/NEJMoa1412098>
11. Diaz-Uriarte R. OncoSimulR: Genetic simulation with arbitrary epistasis and mutator genes in asexual populations. *Bioinformatics*. 2017;33(12):1898–9. doi: [10.1093/bioinformatics/btx077](https://doi.org/10.1093/bioinformatics/btx077)
12. Wang X, Fu AQ, McNERNEY ME, White KP. Widespread genetic epistasis among cancer genes. *Nature Communications*. 2014 Nov;5(1):4828. [accessed 20 Jan 2021] Available from: <https://www.nature.com/articles/ncomms5828>
13. Haar J van de, Canisius S, Yu MK, Voest EE, Wessels LFA, Ideker T. Identifying Epistasis in Cancer Genomes: A Delicate Affair. *Cell*. 2019 May;177(6):1375–83. [accessed 20 Jan 2021] Available from: <http://www.sciencedirect.com/science/article/pii/S0092867419305033>
14. Reia SM, Campos PRA. Analysis of statistical correlations between properties of adaptive walks in fitness landscapes. *Royal Society Open Science*. 7(1):192118. [accessed 20 Jan 2021] Available from: <https://royalsocietypublishing.org/doi/10.1098/rsos.192118>
15. Gu Y, Wang R, Han Y, Zhou W, Zhao Z, Chen T, et al. A landscape of synthetic viable interactions in cancer. *Briefings in Bioinformatics*. 2018 Jul;19(4):644–55. [accessed 20 Jan 2021] Available from: <https://doi.org/10.1093/bib/bbw142>
16. Wood LD, Parsons DW, Jones S, Lin J, Sjöblom T, Leary RJ, et al. The genomic landscapes of human breast and colorectal cancers. *Science*. 2007; doi: [10.1126/science.1145720](https://doi.org/10.1126/science.1145720)
17. Gerstung M, Eriksson N, Lin J, Vogelstein B, Beerenwinkel N. The temporal order of genetic and pathway alterations in tumorigenesis. *PLoS ONE*. 2011;6(10). doi: [10.1371/journal.pone.0027136](https://doi.org/10.1371/journal.pone.0027136)
18. Poelwijk FJ, Kiviet DJ, Weinreich DM, Tans SJ. Empirical fitness landscapes reveal accessible evolutionary paths. *Nature*. 2007;445(7126):383–6. doi: [10.1038/nature05451](https://doi.org/10.1038/nature05451)
19. Yeang C-H, McCormick F, Levine A. Combinatorial patterns of somatic gene mutations in cancer. *The FASEB Journal*. 2008; doi: [10.1096/fj.08-108985](https://doi.org/10.1096/fj.08-108985)